🎀 GYN Oncology — 2026-W41

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Review in JAMA Oncology of treatment intensification and chemosensitization in advanced high-grade serous ovarian cancer with poor chemosensitivity. Synthesizes post hoc phase 3 evidence and chemosensitivity indicators to inform which patients may benefit from intensified systemic therapy before maintenance.

Updated systematic review and network meta-analysis of randomized trials of first-line PARP inhibitor-based maintenance in newly diagnosed advanced ovarian cancer, published in Frontiers in Oncology. Compares efficacy and safety across BRCA and HRD subgroups, helping guide biomarker-directed maintenance selection.

Systematic review of quality-of-life/patient-reported outcomes from pivotal first-line trials in advanced/recurrent endometrial cancer, published in Tumori. Synthesizes how QoL was affected by immunotherapy-chemotherapy combinations across major trials, informing treatment selection discussions beyond efficacy alone.

Large community-based retrospective cohort of endometrial cancer patients, published in Gynecologic Oncology. Estimates germline pathogenic variant prevalence, including Lynch and HRD-related variants, and compares detection by testing indication, informing who should undergo germline testing.

Narrative review of mechanisms of resistance to PARP inhibitors in advanced epithelial ovarian cancer, published in Frontiers in Oncology. Summarizes resistance biology, dynamic biomarkers and emerging combination strategies to overcome resistance.

Retrospective multicenter real-world study (French early access program) of pembrolizumab-lenvatinib in platinum-pretreated advanced/metastatic endometrial cancer, published in ESMO Open. Confirms real-world effectiveness/tolerability consistent with the pivotal trial, including in frailer patients and aggressive histologies underrepresented in prior data.

Preclinical study in Cancer Discovery engineering a collagen-anchored IL-12-armed CAR-NK cell platform tested in ovarian and pancreatic cancer mouse models. Demonstrates improved NK cell persistence and tumor control, an early-stage concept with no clinical data yet.

Pooled patient-level analysis in Cancer evaluating the correlation between progression-free and overall survival in first-line BRCA wild-type advanced ovarian cancer treated with platinum-based chemotherapy. Supports PFS as a reasonable surrogate endpoint in this population, relevant mainly for trial design rather than direct patient management.

Retrospective cohort study in International Journal of Cancer comparing BRCA1/2 carriers with breast-ovarian double primary cancers versus ovarian cancer alone. Finds distinct mutation locations but no difference in survival or PARP inhibitor benefit, reassuring for counseling and treatment of double-primary patients.

Narrative review in Gynecol Oncol evaluating evidence quality for survival benefit of NCCN-recommended risk-reducing interventions (surgery, surveillance, medication) in BRCA1/2 carriers. Highlights that risk-reducing salpingo-oophorectomy has the strongest survival evidence, informing counseling and shared decision-making for high-risk patients.

Preclinical study using cell lines, organoids, and xenograft models in BRCA-deficient ovarian cancer, published in Cancer Research, showing that inhibiting translesion DNA synthesis enhances PARP inhibitor efficacy and delays resistance. Provides rationale for future combination strategies but includes no clinical patient data yet.

Prospective cross-sectional study evaluating serum GLP-1 as a diagnostic marker distinguishing endometrial cancer from polyps and hyperplasia in obese women, published in Gynecol Oncol. Suggests a potential diagnostic biomarker but does not inform treatment selection or report therapeutic outcomes.

Retrospective single-institution real-world study of pembrolizumab, bevacizumab and metronomic cyclophosphamide in heavily pretreated platinum-resistant ovarian cancer, published in Gynecol Oncol. Shows limited activity, arguing against routine use of this regimen given newer options.